drugset / Trial / NCT04521868
A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of the study is to investigate whether adding sulforaphane will benefit the negative symptoms and cognitive function in individuals who have schizophrenia. This study will compare the sulforaphane with placebo. There is a thirty percent change (less than half) of receiving the placebo. The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
Timeline
- Start
- 2020-08-31
- Primary completion
- 2022-08-12
- Completion
- 2022-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sulforaphane | Small molecule | 1700 mg | — |